Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | MDH1 | P40925 | 1/20 | 0.41 |
| ▸ | MDH2 | P40926 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139346 | 0.92 | HIF1A (0.51) | HIF1AEPAS1MEN1RAB9AKMT2A | |
| SCHEMBL3143193 | 0.91 | HIF1A (0.52) | HIF1AEPAS1MEN1RAB9AKMT2A | |
| SCHEMBL3148127 | 0.89 | HIF1A (0.54) | HIF1AEPAS1MEN1RAB9AKMT2A | |
| SCHEMBL3147956 | 0.89 | PDE10A (0.45) | HIF1AEPAS1MEN1RAB9AKMT2A | |
| SCHEMBL4303833 | 0.83 | CASP2 (0.55) | HIF1AEPAS1KMT2A | |
| SCHEMBL4302280 | 0.82 | HIF1A (0.61) | HIF1AEPAS1RAB9A | |
| SCHEMBL3138926 | 0.82 | HIF1A (0.54) | HIF1AEPAS1MEN1RAB9AKMT2A | |
| SCHEMBL4301997 | 0.81 | HIF1A (0.48) | HIF1AEPAS1MEN1KMT2A | |
| SCHEMBL4297513 | 0.80 | HIF1A (0.52) | HIF1AMEN1KMT2A | |
| SCHEMBL3147963 | 0.78 | HIF1A (0.51) | HIF1AEPAS1MEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304448-B2 | Method for the treatment of metabolic disorder containing benzazole derivatives as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-11-06 | — | — | US | claimed |
| US-20100076039-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING BENZAZOLE DERIVATIVES AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY | 2010-03-25 | — | — | US | claimed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | claimed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8304448-B2 | Method for the treatment of metabolic disorder containing benzazole derivatives as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-11-06 | — | — | US | disclosed |
| US-20100076039-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING BENZAZOLE DERIVATIVES AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY | 2010-03-25 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| WO-2009014287-A1 | THE COMPOSITION FOR KILLING INSECTS COMPRISING AZOLE COMPOUNDS AS AN EFFECTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | HIF1A 2/4885EPAS1 14/4885MEN1 3620/4885 |
| US-20100076039-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING BENZAZOLE DERIVATIVES AS AN ACTIVE INGREDIENT | DGAT2, DGAT1, ACAT1 | HIF1A 4095/4885EPAS1 3165/4885MEN1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.